Cwm LLC Increases Position in Moderna, Inc. (NASDAQ:MRNA)

Cwm LLC increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 39.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 169,274 shares of the company’s stock after acquiring an additional 48,141 shares during the period. Cwm LLC’s holdings in Moderna were worth $20,101,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Moderna by 22.6% during the fourth quarter. Vanguard Group Inc. now owns 33,907,072 shares of the company’s stock valued at $3,372,058,000 after acquiring an additional 6,248,623 shares during the last quarter. Norges Bank bought a new position in shares of Moderna during the fourth quarter valued at about $347,565,000. Wellington Management Group LLP raised its stake in shares of Moderna by 28.8% during the fourth quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock valued at $718,584,000 after acquiring an additional 1,614,460 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Moderna by 42.9% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,545,829 shares of the company’s stock valued at $164,724,000 after acquiring an additional 463,960 shares during the last quarter. Finally, Matrix Capital Management Company LP bought a new position in Moderna in the fourth quarter worth about $45,150,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Down 0.9 %

Shares of NASDAQ:MRNA traded down $0.75 during trading on Wednesday, reaching $81.55. 4,318,116 shares of the stock traded hands, compared to its average volume of 4,163,468. The stock has a 50-day moving average of $125.41 and a two-hundred day moving average of $114.75. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.91 and a current ratio of 4.09. The stock has a market cap of $31.25 billion, a P/E ratio of -5.20 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the company posted ($3.62) earnings per share. The business’s revenue for the quarter was down 29.9% on a year-over-year basis. As a group, sell-side analysts expect that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on MRNA. Piper Sandler reissued an “overweight” rating and issued a $157.00 price target (down from $214.00) on shares of Moderna in a research note on Friday, August 2nd. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Thursday, August 1st. Evercore ISI reissued an “in-line” rating and issued a $120.00 price target on shares of Moderna in a research note on Thursday, June 27th. Barclays decreased their price target on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a research note on Friday, August 2nd. Finally, Royal Bank of Canada downgraded shares of Moderna from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $125.00 to $90.00 in a research note on Monday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $124.21.

Insider Activity

In other Moderna news, President Stephen Hoge sold 255 shares of the business’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the sale, the president now owns 1,486,508 shares in the company, valued at approximately $179,808,007.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, President Stephen Hoge sold 255 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $120.96, for a total transaction of $30,844.80. Following the sale, the president now directly owns 1,486,508 shares in the company, valued at approximately $179,808,007.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Shannon Thyme Klinger sold 1,296 shares of the company’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total transaction of $210,561.12. Following the sale, the insider now owns 10,623 shares in the company, valued at $1,725,918.81. The disclosure for this sale can be found here. Insiders sold a total of 381,239 shares of company stock valued at $53,738,737 in the last 90 days. Company insiders own 15.70% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.